Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Ginkgo biloba leaf extract EGb 761® for the treatment of various diseases: Overview of systematic reviews.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pfuhlmann Katrin, Koch Anna K, Langhorst Jost
Аннотация
BACKGROUND: Ginkgo biloba leaf extract EGb 761® might have diverse therapeutic effects.
OBJECTIVE: We conducted an overview of systematic reviews (SRs) to compile the efficacy and safety of EGb 761®.
METHODS: The Cochrane Database of Systematic Reviews, MEDLINE (via PubMed), Embase (via OVID) and PROSPERO were searched from inception until July 25th, 2023 with an update on January 30th, 2025. SRs were included if they evaluated the efficacy and safety of oral treatment with EGb 761® under any clinical condition or in healthy subjects for clinical reasons, such as prevention, or for health promotion. Two authors carried out screening, selection, data extraction and risk of bias assessment (AMSTAR 2). The degree of overlap was quantified. The overview was registered a priori (PROSPERO: CRD42023423789).
RESULTS: We screened 126 articles and included reviews on neurocognitive disorders (n = 13), tinnitus, macular degeneration and schizophrenia (all n = 1). For neurocognitive disorders, most SRs were in favor of EGb 761® regarding cognition and behavioral and/or psychological symptoms, while the results for functional activities of daily living varied. EGb 761® might have positive effects on tinnitus, macular degeneration or schizophrenia: however, more evidence is needed. In general, EGb 761® appears to be safe. Methodological quality was poor in all SRs. The overall overlap of the primary studies on neurocognitive disorders was very high, and pairwise overlap varied.
CONCLUSION: EGb 761® has been studied in various reviews, particularly regarding neurocognitive disorders and has been reported to be safe in many SRs. The results must be treated with caution due to the poor quality of the SRs.
OBJECTIVE: We conducted an overview of systematic reviews (SRs) to compile the efficacy and safety of EGb 761®.
METHODS: The Cochrane Database of Systematic Reviews, MEDLINE (via PubMed), Embase (via OVID) and PROSPERO were searched from inception until July 25th, 2023 with an update on January 30th, 2025. SRs were included if they evaluated the efficacy and safety of oral treatment with EGb 761® under any clinical condition or in healthy subjects for clinical reasons, such as prevention, or for health promotion. Two authors carried out screening, selection, data extraction and risk of bias assessment (AMSTAR 2). The degree of overlap was quantified. The overview was registered a priori (PROSPERO: CRD42023423789).
RESULTS: We screened 126 articles and included reviews on neurocognitive disorders (n = 13), tinnitus, macular degeneration and schizophrenia (all n = 1). For neurocognitive disorders, most SRs were in favor of EGb 761® regarding cognition and behavioral and/or psychological symptoms, while the results for functional activities of daily living varied. EGb 761® might have positive effects on tinnitus, macular degeneration or schizophrenia: however, more evidence is needed. In general, EGb 761® appears to be safe. Methodological quality was poor in all SRs. The overall overlap of the primary studies on neurocognitive disorders was very high, and pairwise overlap varied.
CONCLUSION: EGb 761® has been studied in various reviews, particularly regarding neurocognitive disorders and has been reported to be safe in many SRs. The results must be treated with caution due to the poor quality of the SRs.